Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.19
NAS:DEPO's Cash-to-Debt is ranked lower than
79% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.05 vs. NAS:DEPO: 0.19 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:DEPO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14  Med: 10.3 Max: No Debt
Current: 0.19
Equity-to-Asset 0.20
NAS:DEPO's Equity-to-Asset is ranked lower than
93% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NAS:DEPO: 0.20 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:DEPO' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.63  Med: 0.35 Max: 0.97
Current: 0.2
-2.63
0.97
Debt-to-Equity 2.98
NAS:DEPO's Debt-to-Equity is ranked lower than
97% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. NAS:DEPO: 2.98 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:DEPO' s Debt-to-Equity Range Over the Past 10 Years
Min: -8.32  Med: 0.36 Max: 5.13
Current: 2.98
-8.32
5.13
Interest Coverage 0.11
NAS:DEPO's Interest Coverage is ranked lower than
99% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 112.31 vs. NAS:DEPO: 0.11 )
Ranked among companies with meaningful Interest Coverage only.
NAS:DEPO' s Interest Coverage Range Over the Past 10 Years
Min: 0.11  Med: 8.12 Max: No Debt
Current: 0.11
Piotroski F-Score: 5
Altman Z-Score: 0.39
Beneish M-Score: -3.36
WACC vs ROIC
9.62%
38.84%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 1.98
NAS:DEPO's Operating Margin % is ranked lower than
59% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.95 vs. NAS:DEPO: 1.98 )
Ranked among companies with meaningful Operating Margin % only.
NAS:DEPO' s Operating Margin % Range Over the Past 10 Years
Min: -49.06  Med: 4.94 Max: 72.49
Current: 1.98
-49.06
72.49
Net Margin % -26.02
NAS:DEPO's Net Margin % is ranked lower than
80% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.06 vs. NAS:DEPO: -26.02 )
Ranked among companies with meaningful Net Margin % only.
NAS:DEPO' s Net Margin % Range Over the Past 10 Years
Min: -43.92  Med: -7.32 Max: 75.05
Current: -26.02
-43.92
75.05
ROE % -43.22
NAS:DEPO's ROE % is ranked lower than
84% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.91 vs. NAS:DEPO: -43.22 )
Ranked among companies with meaningful ROE % only.
NAS:DEPO' s ROE % Range Over the Past 10 Years
Min: -90.05  Med: -1.11 Max: 532.43
Current: -43.22
-90.05
532.43
ROA % -9.24
NAS:DEPO's ROA % is ranked lower than
77% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. NAS:DEPO: -9.24 )
Ranked among companies with meaningful ROA % only.
NAS:DEPO' s ROA % Range Over the Past 10 Years
Min: -23.58  Med: -1.26 Max: 73.87
Current: -9.24
-23.58
73.87
ROC (Joel Greenblatt) % 25.09
NAS:DEPO's ROC (Joel Greenblatt) % is ranked higher than
94% of the 793 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.48 vs. NAS:DEPO: 25.09 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:DEPO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2282.52  Med: 123.58 Max: 8060.52
Current: 25.09
-2282.52
8060.52
3-Year Revenue Growth Rate 47.20
NAS:DEPO's 3-Year Revenue Growth Rate is ranked higher than
96% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. NAS:DEPO: 47.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:DEPO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -74.4  Med: 39.55 Max: 517.8
Current: 47.2
-74.4
517.8
3-Year EBITDA Growth Rate 95.70
NAS:DEPO's 3-Year EBITDA Growth Rate is ranked higher than
96% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. NAS:DEPO: 95.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:DEPO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -55.3  Med: 7.6 Max: 95.7
Current: 95.7
-55.3
95.7
GuruFocus has detected 4 Warning Signs with Depomed Inc $NAS:DEPO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:DEPO's 30-Y Financials

Financials (Next Earnings Date: 2017-11-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

DEPO Guru Trades in Q3 2016

Jeremy Grantham 102,300 sh (New)
John Hussman 100,000 sh (New)
Joel Greenblatt 77,542 sh (+63.87%)
Jeremy Grantham 500,000 sh (unchged)
» More
Q4 2016

DEPO Guru Trades in Q4 2016

Mario Gabelli 15,000 sh (New)
Jeremy Grantham 256,509 sh (+150.74%)
John Hussman 150,000 sh (+50.00%)
Jeremy Grantham 500,000 sh (unchged)
Joel Greenblatt Sold Out
» More
Q1 2017

DEPO Guru Trades in Q1 2017

Jim Simons 218,438 sh (New)
Joel Greenblatt 60,893 sh (New)
Paul Tudor Jones 19,800 sh (New)
Mario Gabelli 47,000 sh (+213.33%)
John Hussman 304,200 sh (+102.80%)
Jeremy Grantham Sold Out
» More
Q2 2017

DEPO Guru Trades in Q2 2017

Discovery Group I, LLC 1,658,826 sh (New)
Mario Gabelli 55,000 sh (+17.02%)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Jim Simons 198,438 sh (-9.16%)
John Hussman 150,000 sh (-50.69%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:DEPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2017-06-30 Add 17.02%$9.5 - $13.75 $ 5.93-47%55,000
Joel Greenblatt 2017-06-30 Sold Out 0.01%$9.5 - $13.75 $ 5.93-47%0
Joel Greenblatt 2017-03-31 New Buy0.01%$12.55 - $21.31 $ 5.93-65%60,893
Mario Gabelli 2017-03-31 Add 213.33%$12.55 - $21.31 $ 5.93-65%47,000
Mario Gabelli 2016-12-31 New Buy$17.59 - $26.01 $ 5.93-72%15,000
Joel Greenblatt 2016-12-31 Sold Out 0.03%$17.59 - $26.01 $ 5.93-72%0
Joel Greenblatt 2016-09-30 Add 63.87%0.01%$18.55 - $25.3 $ 5.93-72%77,542
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:TLGT, NAS:TTPH, NAS:PETQ, NAS:ACET, NAS:COLL, NAS:RIGL, NAS:ADMS, NAS:SNDX, NAS:KPTI, NAS:NEOS, NAS:TOCA, NAS:DRRX, NAS:SCMP, TSXV:ZOM, NAS:CPRX, NAS:SCLN, NAS:SGYP, OTCPK:OPTI, NAS:ADMP, NYSE:LCI » details
Traded in other countries:DPO.Germany,
Headquarter Location:USA
Depomed Inc is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system.

Depomed is a specialty and generic drug manufacturer. The company is focused on pain and central nervous system conditions. Depomed operates solely in the United States. It also has recognized license and royalty revenue from license agreements in the territories of the U.S., Canada, and Korea. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Top Ranked Articles about Depomed Inc

The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Depomed, Inc. Shareholders and a Lead Plaintiff Deadline of October 17, 2017 (DEPO)
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Depomed, Inc. (Nasdaq: DEPO) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
DEPO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Depomed, Inc. and a Lead Plaintiff Deadline of October 17, 2017
RM LAW Announces Class Action Lawsuit Against Depomed, Inc.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Depomed, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 17, 2017 – DEPO
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Depomed, Inc. – DEPO
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
Depomed to Present at the Morgan Stanley Global Healthcare Conference
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Depomed, Inc. of Class Action Lawsuit and Upcoming Deadline – DEPO

Ratios

vs
industry
vs
history
Forward PE Ratio 7.05
DEPO's Forward PE Ratio is ranked higher than
67% of the 67 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.90 vs. DEPO: 7.05 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 6.36
DEPO's Price-to-Owner-Earnings is ranked higher than
89% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.90 vs. DEPO: 6.36 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DEPO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.68  Med: 8.2 Max: 212
Current: 6.36
2.68
212
PB Ratio 1.78
DEPO's PB Ratio is ranked lower than
51% of the 751 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. DEPO: 1.78 )
Ranked among companies with meaningful PB Ratio only.
DEPO' s PB Ratio Range Over the Past 10 Years
Min: 1.75  Med: 4.17 Max: 22.64
Current: 1.78
1.75
22.64
PS Ratio 0.85
DEPO's PS Ratio is ranked higher than
73% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. DEPO: 0.85 )
Ranked among companies with meaningful PS Ratio only.
DEPO' s PS Ratio Range Over the Past 10 Years
Min: 0.84  Med: 3.18 Max: 24.62
Current: 0.85
0.84
24.62
Price-to-Free-Cash-Flow 4.06
DEPO's Price-to-Free-Cash-Flow is ranked higher than
91% of the 208 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.89 vs. DEPO: 4.06 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DEPO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 2.37  Med: 10.46 Max: 291.05
Current: 4.06
2.37
291.05
Price-to-Operating-Cash-Flow 4.04
DEPO's Price-to-Operating-Cash-Flow is ranked higher than
87% of the 277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.02 vs. DEPO: 4.04 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DEPO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.35  Med: 10.28 Max: 271.08
Current: 4.04
2.35
271.08
EV-to-EBIT 228.15
DEPO's EV-to-EBIT is ranked lower than
90% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. DEPO: 228.15 )
Ranked among companies with meaningful EV-to-EBIT only.
DEPO' s EV-to-EBIT Range Over the Past 10 Years
Min: -302.2  Med: -1.7 Max: 309.7
Current: 228.15
-302.2
309.7
EV-to-EBITDA 8.01
DEPO's EV-to-EBITDA is ranked higher than
80% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.50 vs. DEPO: 8.01 )
Ranked among companies with meaningful EV-to-EBITDA only.
DEPO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -582.9  Med: 2.5 Max: 124.5
Current: 8.01
-582.9
124.5
EV-to-Revenue 2.07
DEPO's EV-to-Revenue is ranked higher than
57% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.22 vs. DEPO: 2.07 )
Ranked among companies with meaningful EV-to-Revenue only.
DEPO' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.2  Med: 2.8 Max: 22.1
Current: 2.07
0.2
22.1
Shiller PE Ratio 59.18
DEPO's Shiller PE Ratio is ranked lower than
81% of the 198 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 39.37 vs. DEPO: 59.18 )
Ranked among companies with meaningful Shiller PE Ratio only.
DEPO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 58.48  Med: 117.73 Max: 1535
Current: 59.18
58.48
1535
Current Ratio 0.79
DEPO's Current Ratio is ranked lower than
91% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. DEPO: 0.79 )
Ranked among companies with meaningful Current Ratio only.
DEPO' s Current Ratio Range Over the Past 10 Years
Min: 0.57  Med: 2.82 Max: 56
Current: 0.79
0.57
56
Quick Ratio 0.75
DEPO's Quick Ratio is ranked lower than
80% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.82 vs. DEPO: 0.75 )
Ranked among companies with meaningful Quick Ratio only.
DEPO' s Quick Ratio Range Over the Past 10 Years
Min: 0.57  Med: 2.71 Max: 56
Current: 0.75
0.57
56
Days Inventory 51.86
DEPO's Days Inventory is ranked higher than
83% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. DEPO: 51.86 )
Ranked among companies with meaningful Days Inventory only.
DEPO' s Days Inventory Range Over the Past 10 Years
Min: 49.12  Med: 208.69 Max: 544.34
Current: 51.86
49.12
544.34
Days Sales Outstanding 67.22
DEPO's Days Sales Outstanding is ranked higher than
68% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. DEPO: 67.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
DEPO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.13  Med: 29.91 Max: 81.71
Current: 67.22
12.13
81.71
Days Payable 56.33
DEPO's Days Payable is ranked lower than
85% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.96 vs. DEPO: 56.33 )
Ranked among companies with meaningful Days Payable only.
DEPO' s Days Payable Range Over the Past 10 Years
Min: 30.8  Med: 91.87 Max: 159.38
Current: 56.33
30.8
159.38

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.60
DEPO's 3-Year Average Share Buyback Ratio is ranked higher than
58% of the 473 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. DEPO: -2.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DEPO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -58.9  Med: -7.55 Max: -2.2
Current: -2.6
-58.9
-2.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.75
DEPO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
69% of the 328 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. DEPO: 0.75 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DEPO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.74  Med: 2.23 Max: 335
Current: 0.75
0.74
335
Price-to-Median-PS-Value 0.27
DEPO's Price-to-Median-PS-Value is ranked higher than
93% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. DEPO: 0.27 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DEPO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.27  Med: 1.75 Max: 394
Current: 0.27
0.27
394
Earnings Yield (Greenblatt) % 0.43
DEPO's Earnings Yield (Greenblatt) % is ranked lower than
63% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. DEPO: 0.43 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DEPO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -213.8  Med: -0.45 Max: 266.4
Current: 0.43
-213.8
266.4

More Statistics

Revenue (TTM) (Mil) $425.34
EPS (TTM) $ -1.79
Beta0.80
Short Percentage of Float17.22%
52-Week Range $5.81 - 27.02
Shares Outstanding (Mil)62.99

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 407 438 463
EPS ($) 0.52 0.81 0.93
EPS without NRI ($) 0.52 0.81 0.93
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:DEPO

Headlines

Articles On GuruFocus.com
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Inve Sep 19 2017 
DEPO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving D Sep 18 2017 
RM LAW Announces Class Action Lawsuit Against Depomed, Inc. Sep 15 2017 
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Depomed, Inc. of a Class Action Law Sep 15 2017 
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Depomed, In Sep 13 2017 
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed Sep 12 2017 
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dep Sep 11 2017 
Depomed to Present at the Morgan Stanley Global Healthcare Conference Sep 05 2017 
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sep 02 2017 
The Klein Law Firm Announces a Class Action Filed on Behalf of Depomed, Inc. Shareholders and a Lead Sep 01 2017 

More From Other Websites
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and... Sep 20 2017
The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Depomed,... Sep 20 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in... Sep 19 2017
INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc.... Sep 19 2017
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From... Sep 19 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Depomed, Inc. of a Class Action... Sep 19 2017
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and... Sep 18 2017
DEPO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving... Sep 18 2017
SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc.... Sep 15 2017
IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed,... Sep 14 2017
The Klein Law Firm Notifies Investors of Commencement of a Class Action Filed on Behalf of Depomed,... Sep 14 2017
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Depomed, Inc.... Sep 14 2017
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Depomed,... Sep 13 2017
IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed,... Sep 13 2017
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Depomed, Inc. of Commencement of a Class... Sep 13 2017
See what the IHS Markit Score report has to say about Depomed Inc. Sep 13 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}